Related Experiment Video

Updated: Jun 10, 2026

Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

Management of myocardial infarction in children with Kawasaki disease

Nethnapha Paredes1, Tapas Mondal, Leonardo R Brandão

  • 1Thrombosis & Atherosclerosis Research Institute (TaARI), Hamilton General Hospital Campus, McMaster University, Hamilton, Ontario, Canada.

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|August 19, 2010
PubMed

Insights

Kawasaki disease can lead to heart attack in children. This review examines treatments for myocardial infarction in pediatric patients with Kawasaki disease, noting varied outcomes with current therapies.

Area of Science:

  • Pediatric Cardiology
  • Rheumatology
  • Vascular Biology

Background:

  • Kawasaki disease is a critical systemic vasculitis impacting infants and children.
  • Coronary aneurysms develop in up to 5% of patients despite treatment, increasing risks of myocardial infarction and death.
  • Established myocardial infarction treatment protocols for adults lack pediatric-specific guidance, especially for Kawasaki disease.

Purpose of the Study:

  • To review current data on managing myocardial infarction in children with Kawasaki disease.
  • To summarize the use and outcomes of various thrombolytic agents and glycoprotein IIb/IIIa inhibitors.
  • To highlight the need for specific treatment recommendations for pediatric myocardial infarction in Kawasaki disease.

Main Methods:

  • Systematic review of published case reports and studies.
  • Analysis of therapeutic interventions for myocardial infarction in pediatric Kawasaki disease patients.
  • Evaluation of outcomes associated with thrombolytic agents (streptokinase, urokinase, tissue plasminogen activator) and abciximab.

Main Results:

  • Limited data exists on treating myocardial infarction in pediatric Kawasaki disease.
  • Reported use of thrombolytic agents and abciximab shows varied patient outcomes.
  • No established clinical trials or dosing guidelines for thrombolytic therapy in this population.

Conclusions:

  • Management of myocardial infarction in children with Kawasaki disease remains challenging.
  • Further research and clinical trials are essential to establish effective treatment protocols.
  • Specific guidelines are needed for thrombolytic and antiplatelet therapies in pediatric Kawasaki disease patients with myocardial infarction.

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...